Table 3.
Clinical trials with chimeric antigen receptor T cells cells in hepatocellular carcinoma
| NCT | Antigen | Phase | Patients | Sponsor | Status | Comments |
| NCT02715362 | GPC3 | I/II | 30 | Company | Recruiting | HAI |
| NCT03672305 | c-Met/PD-L1 | I | 50 | Academic | Not yet recruiting | IV |
| NCT02723942 | GPC3 | I/II | 60 | Academic | Completed | |
| NCT03198546 | GPC3 | I | 30 | Academic | Recruiting | |
| NCT02395250 | GPC3 | I | 13 | Academic | Completed | [58] |
| NCT03349255 | AFP | I | 18 | Company | Recruiting | IV vs HAI |
| NCT03130712 | GPC3 | I/II | 10 | Company | Recruiting | IT |
| NCT03084380 | GPC3 | I/II | 20 | Academic | Not yet recruiting | Combination with TACE |
| NCT029051881 | GPC3 | I | 14 | Academic | Not yet recruiting | |
| NCT03302403 | GPC3 | I | 48 | Academic | Not yet recruiting | |
| NCT03146234 | GPC3 | I | 20 | Academic | Recruiting | |
| NCT01935843 | Her2 | I/II | 10 | Academic | Unknown | |
| NCT02959151 | GPC3 | I/II | 20 | Company | Unknown | |
| NCT02587689 | MUC1 | I/II | 20 | Company | Unknown | |
| NCT03013712 | EpCAM | I/II | 60 | Academic | Recruiting |
1
Location of study is United States, all other trials are conducted in China. HAI: Hepatic artery infusion; IT: Intratumoral injection; IV: Intravenous injection; TACE: Transarterial chemoembolization.